• Alliance Global Partners maintains a "Buy" rating for NASDAQ:OGI, raising the price target from C$3.60 to C$4.
• Organigram reported a quarterly loss of C$(0.283) per share, significantly below the Zacks Consensus Estimate.
• The company's revenue for the quarter ending September 2025 was C$80.1 million, exceeding the Zacks Consensus Estimate by 7.1%.

Organigram Holdings Inc. (NASDAQ:OGI) is a prominent player in the Canadian cannabis industry, known for its recreational cannabis products. As of December 16, 2025, Alliance Global Partners maintained a "Buy" rating for OGI, with the stock priced at approximately $1.91. They also raised the price target from C$3.60 to C$4, indicating confidence in the company's future performance.

Despite the positive outlook from Alliance Global, Organigram reported a quarterly loss of C$(0.283) per share, which was significantly below the Zacks Consensus Estimate. This represents a substantial increase from the $0.04 loss per share reported in the same quarter last year.

However, Organigram's revenue performance tells a different story. For the quarter ending September 2025, the company reported revenue of C$80.1 million, exceeding the Zacks Consensus Estimate by 7.1%. The company has surpassed consensus revenue estimates in three of the last four quarters, showcasing its ability to grow sales despite earnings challenges.

Organigram's stock, trading on the NASDAQ, is currently priced at $1.93, reflecting a positive change of 7.5% or an increase of $0.135. The stock has fluctuated between a low of $1.70 and a high of $1.98 during the day. Over the past year, it has reached a high of $2.07 and a low of $0.85. The market capitalization of OGI stands at approximately $259.3 million, with a trading volume of 3,754,420 shares, indicating active investor interest.